Physician profile
Meredith D Floyd
NPI 1538111760
$831.38
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $307 · 2021: $197.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $212.00 | 2019-2021 | |
| Amarin Pharma, INC. | $150.35 | 2019-2020 | |
| Novo Nordisk INC | $110.66 | 2019-2021 | |
| Lilly USA, LLC | $89.25 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $84.93 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.54 | 2019-2021 | |
| Pfizer INC. | $24.57 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $24.22 | 2019 | |
| Shire North American Group INC | $18.87 | 2019 | |
| Amgen INC. | $18.05 | 2019 | |
| Phadia US INC. | $16.67 | 2021 | |
| Glaxosmithkline, LLC. | $14.48 | 2019 | |
| Genentech USA, INC. | $11.79 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Floyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.